Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Hiremath S et al. – The risks and benefits of antiplatelet agents in ESRD patients remain poorly defined. Until a clinical trial addresses this in the dialysis population, individual risk stratification taking into account the increased risk of bleeding should be considered before initiating antiplatelet agents, especially in combination therapy.

Related Articles

Psoas abscess in hemodialysis patients
International Urology and Nephrology, 10/06/09    Relevance Score: 90%

Improved Nutrition After Conversion to Nocturnal Home Hemodialysis
Journal of Renal Nutrition, 10/14/09    Relevance Score: 89%

Permanent Hearing Loss With Iopamidol Following Aortic Angiography in a Hemodialysis Patient: A Case Report and Review of the Literature
American Journal of Kidney Diseases, 10/28/09    Relevance Score: 87%

Prevalence and Cardiovascular Features of Japanese Hemodialysis Patients with Fabry Disease
American Journal of Nephrology, 10/16/09    Relevance Score: 87%

Revised Dyadic Adjustment Scale as a Reliable Tool for Assessment of Quality of Marital Relationship in Patients on Long-Term Hemodialysis
Iranian Journal of Kidney Diseases, 10/13/09    Relevance Score: 87%

Today in Pharmacology/kinetics...keeping you current

Medium-size-vessel vasculitis
Pediatric Nephrology, 12/04/09

Sirolimus and Cyclosporine A Alter Barrier Function In Renal Proximal Tubular Cells through Stimulation of ERK 1/2 Signaling and Claudin-1 Expression
American Journal of Physiology: Renal Physiology, 12/04/09

Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: A prospective evaluation
Urologic Oncology: Seminars and Original Investigations, 12/03/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address